aggressive systemic mastocytosis
Information
- Disease name
- aggressive systemic mastocytosis
- Disease ID
- DOID:4798
- Description
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| KIT | 4 | 54,657,913 | 54,740,770 | 4 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03580655 | Active, not recruiting | Phase 2 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | November 21, 2018 | January 31, 2026 |
| NCT05219266 | Available | Managed Access Programs for PKC412, Midostaurin | |||
| NCT01807598 | Completed | Phase 2 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | September 2013 | September 2017 |
| NCT02561988 | Completed | Phase 1 | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | March 10, 2016 | January 19, 2023 |
| NCT04695431 | Completed | Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM | December 2, 2020 | October 4, 2021 | |
| NCT02415608 | Terminated | Phase 2 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | March 2015 | June 14, 2017 |
- Disase is a (Disease Ontology)
- DOID:349
- Cross Reference ID (Disease Ontology)
- ICD10CM:C96.21
- Cross Reference ID (Disease Ontology)
- MESH:D034721
- Cross Reference ID (Disease Ontology)
- NCI:C9285
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:716655008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1112486
- Exact Synonym (Disease Ontology)
- ASM
- Exact Synonym (Disease Ontology)
- Lymphadenopathic mastocytosis with eosinophilia
- OrphaNumber from OrphaNet (Orphanet)
- 98850